Free Trial

Leerink Partnrs Has Negative Outlook for BBIO Q3 Earnings

BridgeBio Pharma logo with Medical background

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Equities researchers at Leerink Partnrs lowered their Q3 2025 earnings per share estimates for shares of BridgeBio Pharma in a research report issued on Monday, June 30th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($0.79) for the quarter, down from their prior estimate of ($0.78). The consensus estimate for BridgeBio Pharma's current full-year earnings is ($3.67) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma's Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($2.87) EPS, FY2026 earnings at ($1.46) EPS, FY2027 earnings at $0.66 EPS, FY2028 earnings at $3.50 EPS and FY2029 earnings at $5.52 EPS.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported ($0.88) EPS for the quarter, beating analysts' consensus estimates of ($1.00) by $0.12. The firm had revenue of $36.74 million during the quarter, compared to analyst estimates of $57.14 million. The business's revenue for the quarter was down 44.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.20) earnings per share.

A number of other analysts have also recently weighed in on the stock. Piper Sandler upped their target price on shares of BridgeBio Pharma from $46.00 to $63.00 and gave the company an "overweight" rating in a research note on Wednesday, April 30th. Redburn Atlantic started coverage on BridgeBio Pharma in a report on Monday, March 31st. They set a "buy" rating and a $50.00 price objective on the stock. Scotiabank upped their price objective on BridgeBio Pharma from $52.00 to $55.00 and gave the company a "sector outperform" rating in a research note on Wednesday, April 30th. Bank of America increased their target price on BridgeBio Pharma from $50.00 to $54.00 and gave the stock a "buy" rating in a report on Wednesday, June 25th. Finally, UBS Group boosted their price target on BridgeBio Pharma from $65.00 to $72.00 and gave the company a "buy" rating in a research note on Wednesday, April 30th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, BridgeBio Pharma currently has an average rating of "Moderate Buy" and an average price target of $58.85.

Check Out Our Latest Report on BridgeBio Pharma

BridgeBio Pharma Stock Up 2.0%

BridgeBio Pharma stock traded up $0.88 on Thursday, hitting $43.71. The company's stock had a trading volume of 2,459,721 shares, compared to its average volume of 2,510,237. BridgeBio Pharma has a one year low of $21.72 and a one year high of $45.48. The firm has a market cap of $8.30 billion, a P/E ratio of -12.38 and a beta of 1.15. The company has a fifty day moving average price of $37.93 and a 200-day moving average price of $34.75.

Insider Buying and Selling

In related news, major shareholder Global Investors Lp Viking sold 3,500,000 shares of the company's stock in a transaction dated Friday, June 27th. The shares were sold at an average price of $44.00, for a total transaction of $154,000,000.00. Following the transaction, the insider owned 18,555,375 shares in the company, valued at $816,436,500. This represents a 15.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Neil Kumar sold 75,000 shares of the stock in a transaction dated Tuesday, April 22nd. The stock was sold at an average price of $34.11, for a total transaction of $2,558,250.00. Following the sale, the chief executive officer directly owned 4,873,447 shares in the company, valued at approximately $166,233,277.17. This represents a 1.52% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 9,936,181 shares of company stock valued at $375,878,164. Insiders own 18.20% of the company's stock.

Institutional Trading of BridgeBio Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of BBIO. Rhumbline Advisers lifted its holdings in BridgeBio Pharma by 0.5% during the 1st quarter. Rhumbline Advisers now owns 220,128 shares of the company's stock worth $7,610,000 after buying an additional 1,008 shares in the last quarter. Strs Ohio bought a new stake in shares of BridgeBio Pharma during the first quarter worth $408,000. Wealth Management Associates Inc. raised its position in shares of BridgeBio Pharma by 19.0% during the first quarter. Wealth Management Associates Inc. now owns 8,980 shares of the company's stock worth $310,000 after acquiring an additional 1,435 shares during the last quarter. Intech Investment Management LLC lifted its stake in shares of BridgeBio Pharma by 12.0% during the first quarter. Intech Investment Management LLC now owns 73,524 shares of the company's stock valued at $2,542,000 after acquiring an additional 7,877 shares during the period. Finally, Zimmer Partners LP boosted its holdings in BridgeBio Pharma by 67.1% in the first quarter. Zimmer Partners LP now owns 301,400 shares of the company's stock valued at $10,419,000 after acquiring an additional 121,000 shares during the last quarter. Institutional investors and hedge funds own 99.85% of the company's stock.

BridgeBio Pharma Company Profile

(Get Free Report)

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

Featured Articles

Earnings History and Estimates for BridgeBio Pharma (NASDAQ:BBIO)

Should You Invest $1,000 in BridgeBio Pharma Right Now?

Before you consider BridgeBio Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BridgeBio Pharma wasn't on the list.

While BridgeBio Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines